Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 9/2014

01-09-2014 | Hypertension and the Kidney (RM Carey, Section Editor)

Renal Generation of Angiotensin II and the Pathogenesis of Hypertension

Authors: Jorge F. Giani, Tea Janjulia, Brian Taylor, Ellen A. Bernstein, Kandarp Shah, Xiao Z. Shen, Alicia A. McDonough, Kenneth E. Bernstein, Romer A. Gonzalez-Villalobos

Published in: Current Hypertension Reports | Issue 9/2014

Login to get access

Abstract

The existence of a complete and functional renin-angiotensin system along the nephron is widely recognized. However, its precise role in blood pressure control and, by extension, hypertension is still uncertain. While most investigators agree that overexpressing RAS components along the nephron results in hypertension, two important issues remain: whether the local RAS works as a separate entity or represents an extension of the systemic RAS and whether locally generated angiotensin II has specific renal effects on blood pressure that are distinct from systemic angiotensin II. This review addresses these issues while emphasizing the unique role of local angiotensin II in the response of the kidney to hypertensive stimuli and the induction of hypertension.
Literature
1.
Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension. 1999;34(6):1265–74.PubMedCrossRef
2.
Navar LG, Lewis L, Hymel A, Braam B, Mitchell KD. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J Am Soc Nephrol. 1994;5(4):1153–8.PubMed
3.
Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension. 2001;37(5):1329–35.PubMedCentralPubMedCrossRef
4.
Lavoie JL, Lake-Bruse KD, Sigmund CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol. 2004;286(5):F965–71.PubMedCrossRef
5.
Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, Brezniceanu ML, et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int. 2006;69(6):1016–23.PubMedCrossRef
6.
Kobori H, Ozawa Y, Satou R, Katsurada A, Miyata K, Ohashi N, et al. Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol. 2007;293(3):F938–45.PubMedCentralPubMedCrossRef
7.•
Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol. 2012. This manuscripts demonstrates that liver angiotensinogen is the main source for angiotensin peptides, under basal conditions, in mice
8.
Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol. 2001;12(3):431–9.PubMedCentralPubMed
9.
Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, et al. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal physiol. 2008;295(3):F772–9.PubMedCentralPubMedCrossRef
10.
Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 2002;61(2):579–85.PubMedCentralPubMedCrossRef
11.•
Navar LG. Translational studies on augmentation of intratubular renin-angiotensin system in hypertension. Kidney inter, Suppl. 2013;3(4):321–5. This manuscript summarizes recent advances in urinary angiotensinogen excretion as a marker for renal human RAS activation.CrossRef
12.
13.
Prieto MC, Gonzalez AA, Navar LG. Evolving concepts on regulation and function of renin in distal nephron. Pflugers Archiv: Eur J Physiol. 2013;465(1):121–32.CrossRef
14.
Ramkumar N, Ying J, Stuart D, Kohan DE. Overexpression of renin in the collecting duct causes elevated blood pressure. Am J Hypertens. 2013;26(8):965–72.PubMedCrossRef
15.
Alhenc-Gelas F, Baussant T, Hubert C, Soubrier F, Corvol P. The angiotensin converting enzyme in the kidney. J Hypertens Suppl : Off J Int Soc Hypertens. 1989;7(7):S9–13. discussion S4.CrossRef
16.
Casarini DE, Boim MA, Stella RC, Krieger-Azzolini MH, Krieger JE, Schor N. Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron. Am J Physiol. 1997;272(3 Pt 2):F405–9.PubMed
17.
Paxton WG, Runge M, Horaist C, Cohen C, Alexander RW, Bernstein KE. Immunohistochemical localization of rat angiotensin II AT1 receptor. Am J Physiol. 1993;264(6 Pt 2):F989–95.PubMed
18.
Gonzalez-Villalobos RA, Billet S, Kim C, Satou R, Fuchs S, Bernstein KE, et al. Intrarenal angiotensin-converting enzyme induces hypertension in response to angiotensin I infusion. J Am Soc Nephrol. 2011;22(3):449–59.PubMedCentralPubMedCrossRef
19.
Shao W, Seth DM, Navar LG. Augmenation of endogenous angiotensin II levels in Val5-Ang II infused rats. JIM. 2008;56(1):344–492.
20.
Gonzalez-Villalobos RA, Satou R, Ohashi N, Semprun-Prieto LC, Katsurada A, Kim C, et al. Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition. Am J Physiol Renal Physiol. 2010;298(1):F150–7.PubMedCentralPubMedCrossRef
21.
22.
Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol. 2011;11(2):180–6.PubMedCentralPubMedCrossRef
23.
Graciano ML, Cavaglieri RDC, Delle H, Dominguez WV, Casarini DE, Malheiros DMAC, et al. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol. 2004;15(7):1805–15.PubMedCrossRef
24.
Acres OW, Satou R, Navar LG, Kobori H. Contribution of a nuclear factor-kappaB binding site to human angiotensinogen promoter activity in renal proximal tubular cells. Hypertension. 2011;57(3):608–13.PubMedCentralPubMedCrossRef
25.
Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Katsurada A, Navar LG, et al. Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. Am J Physiol Renal Physiol. 2008;295(1):F283–9.PubMedCentralPubMedCrossRef
26.
Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Urushihara M, Acres OW, et al. IL-6 augments angiotensinogen in primary cultured renal proximal tubular cells. Mol Cell Endocrinol. 2009;311(1–2):24–31.PubMedCentralPubMedCrossRef
27.
Satou R, Miyata K, Gonzalez-Villalobos RA, Ingelfinger JR, Navar LG, Kobori H. Interferon-gamma biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. Faseb J. 2012;26(5):1821–30.PubMedCentralPubMedCrossRef
28.
Rodriguez-Iturbe B, Franco M, Johnson RJ. Impaired pressure natriuresis is associated with interstitial inflammation in salt-sensitive hypertension. Curr Opin Nephrol Hypertens. 2013;22(1):37–44.PubMedCrossRef
29.
Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res. 2010;33(10):975–80.PubMedCrossRef
30.
Fagard RH, Cowley Jr AW, Navar LG, Langford HG, Guyton AC. Renal responses to slight elevations of renal arterial plasma angiotensin II concentration in dogs. Clin Exp Pharmacol & Physiol. 1976;3(6):531–8.CrossRef
31.
Kimbrough Jr HM, Vaughan Jr ED, Carey RM, Ayers CR. Effect of intrarenal angiotensin II blockade on renal function in conscious dogs. Circ Res. 1977;40(2):174–8.PubMedCrossRef
32.
Navar LG, Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. Kidney Int. 1984;25(6):857–68.PubMedCrossRef
33.
Rosivall L, Carmines PK, Navar LG. Effects of renal arterial angiotensin I infusion on glomerular dynamics in sodium replete dogs. Kidney Int. 1984;26(3):263–8.PubMedCrossRef
34.•
Levens NR, Peach MJ, Carey RM. Role of the intrarenal renin-angiotensin system in the control of renal function. Circ Res. 1981;48(2):157–67. This manuscript assesses the state of science concerning the renal RAS in the seventies and eighties.PubMedCrossRef
35.
Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P, et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension. 2004;43(4):854–9.PubMedCrossRef
36.
Cole J, Quach DL, Sundaram K, Corvol P, Capecchi MR, Bernstein KE. Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res. 2002;90(1):87–92.PubMedCrossRef
37.
Shen XZ, Li P, Weiss D, Fuchs S, Xiao HD, Adams JA, et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol. 2007;170(6):2122–34.PubMedCentralPubMedCrossRef
38.••
Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, Nguyen MT, Riquier-Brison AD, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest. 2013;123(5):2011–23. This manuscript supports the concept of an obligatory role of renal angiotensin II in the development of hypertension. A detailed analysis of the renal ACE/angiotensin II pathway actions during angiotensin II-dependent hypertension is offered.PubMedCentralPubMedCrossRef
39.••
Guyton AC. Blood pressure control--special role of the kidneys and body fluids. Science. 1991;252(5014):1813–6. This manuscript describes the role of the renal ACE/angiotensin II pathway in the hypertension induced by L-NAME, a low renin form of hypertension.PubMedCrossRef
40.
Giani JF, Janjulia T, Kamat N, Seth DM, Blackwell W-LB, Shah KH et al. Renal angiotensin-converting enzyme is essential for the Hypertension induced by Nitric Oxide Synthesis Inhibition. J Am Soc Nephrol. 2014;In press
41.
Schreiber A, Shulhevich Y, Geraci S, Hesser J, Stsepankou D, Neudecker S, et al. Transcutaneous measurement of renal function in conscious mice. Am J Physiol Renal Physiol. 2012;303(5):F783–8.PubMedCrossRef
Metadata
Title
Renal Generation of Angiotensin II and the Pathogenesis of Hypertension
Authors
Jorge F. Giani
Tea Janjulia
Brian Taylor
Ellen A. Bernstein
Kandarp Shah
Xiao Z. Shen
Alicia A. McDonough
Kenneth E. Bernstein
Romer A. Gonzalez-Villalobos
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 9/2014
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0477-1

Other articles of this Issue 9/2014

Current Hypertension Reports 9/2014 Go to the issue

Hypertension and the Brain (S Stocker, Section Editor)

Chemoreflexes, Sleep Apnea, and Sympathetic Dysregulation

Preeclampsia (VD Garovic, Section Editor)

Treatment of Preeclampsia: Current Approach and Future Perspectives

Blood Pressure Monitoring and Management (G Ogedegbe and JA Staessen, Section Editors)

Cardiovascular Risk Stratification and Blood Pressure Variability on Ambulatory and Home Blood Pressure Measurement

Blood Pressure Monitoring and Management (G Ogedegbe and JA Staessen, Section Editors)

The Complexity of Masked Hypertension: Diagnostic and Management Challenges

Hypertension and the Brain (S Stocker, Section Editor)

Neuroinflammation in Pulmonary Hypertension: Concept, Facts, and Relevance

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

New Insights into Carbonic Anhydrase Inhibition, Vasodilation, and Treatment of Hypertensive-Related Diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits